1. Pink Sheet
  2. >>Market Access

Patient-Doc Task Force Building Legal Case Against Alternative Funding Programs

 
• By Sarah Karlin-Smith

From illegal importation under FDCA to possible ERISA, HIPAA and ACA violations – a task force led by CancerCare is pushing regulatory agencies with levers to go after employer plans use of alternative funding programs for specialty drugs, which they say violate multiple federal laws. 

person in business suit building a wooden block tower
Task force is building a multi-layered case against alternative funding programs that alter specialty drug coverage • Source: Shutterstock

A task force of more than a dozen groups representing patients, doctors and a variety of disease areas – many of whom receive pharma industry support – is aiming to build a legal case against alternative funding programs that they hope will convince federal regulators, particularly the US Department of Labor, to quash the use of this tactic for specialty drug coverage.

Alternative funding programs (AFPs) are a relatively new strategy employed mostly by self-funded employer plans, whereby the plans carve out...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

MSD Works To Reverse English Funding Refusal For Winrevair; Reimbursement Plans Progress Elsewhere

 
• By Neena Brizmohun

MSD is gearing up to demonstrate the value of its pulmonary arterial hypertension drug, after England’s health technology assessment institute provisionally said the product was not cost-effective. Meanwhile, the company told the Pink Sheet about Winrevair’s reimbursement status across Europe.

China NHSA Releases Preliminary Innovative Drug List For First Time

 
• By Xu Hu

China’s NHSA in August released for the first time a preliminary list of innovative drugs under commercial insurance, along with a preliminary list of products under the National Reimbursement Drug List.

Changes In Pediatric COVID-19 Vaccine Recommendations Causing Coverage Confusion

 
• By Sue Sutter

The CDC’s current shared clinical decision-making recommendation for vaccinating healthy children age six months and older should trigger full coverage under the Affordable Care Act, but is not always happening at pharmacies and doctors’ offices, an Epstein Becker attorney said.

UK Drug Pricing Scheme Talks Collapse: Industry Braces For Another Year Of High Rebates

 
• By Eliza Slawther

Talks between the UK government and the pharmaceutical industry that were intended to resolve issues around high clawback rates under the voluntary pricing scheme for branded medicines have failed, meaning that the mechanism used to calculate rebates will remain in place.

More from Pink Sheet

EMA Learns Hard Lessons From US-Inspired Streamlining Pilot

 
• By Vibha Sharma

The European Medicines Agency’s ongoing pilot to streamline drug reviews by allowing companies to voluntarily pre-fill factual data in assessment report templates appears to add significant workload for industry, without delivering clear value to regulators.

UK Drug Pricing Scheme Talks Collapse: Industry Braces For Another Year Of High Rebates

 
• By Eliza Slawther

Talks between the UK government and the pharmaceutical industry that were intended to resolve issues around high clawback rates under the voluntary pricing scheme for branded medicines have failed, meaning that the mechanism used to calculate rebates will remain in place.

US FDA Suspends Valneva’s Ixchiq Based On Four New Serious AE Reports

 
• By Sue Sutter

After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.